GC Pharma getting closer to world’s first commercialized recombinant protein for hepatitis B

Published: 2018-01-19 09:49:38

Updated: 2018-01-19 09:49:38

GC Pharma(CEO Eun-Cheol Huh), formally known as Green Cross, announced on the 18^th that the Phase II/III clinical trial plan for ‘GC1102(Hepabig-gene),’ a recombinant immunoglobulin for the treatment of hepatitis B, has acquired approval from the Ministry of Food and Drug Safety.

The hepatitis B immunoglobulin, a protein working as an antibody against hepatitis B virus, is manufactured as a me...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.